Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Friday morning, Benzinga reports. Needham & Company LLC currently has a $8.00 price target on the biopharmaceutical company’s stock.

Several other research analysts have also recently commented on ESPR. HC Wainwright reiterated a buy rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday. Bank of America cut Esperion Therapeutics from a neutral rating to an underperform rating and cut their price objective for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. Finally, StockNews.com cut Esperion Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, May 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and an average price target of $8.83.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $2.22 on Friday. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The business’s 50-day simple moving average is $2.31 and its 200 day simple moving average is $2.39. The stock has a market cap of $420.60 million, a price-to-earnings ratio of -2.24 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.42. The business had revenue of $137.74 million during the quarter, compared to analyst estimates of $53.11 million. On average, equities research analysts predict that Esperion Therapeutics will post -0.05 EPS for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Spire Wealth Management grew its holdings in shares of Esperion Therapeutics by 69.2% during the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 7,267 shares during the last quarter. Private Portfolio Partners LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $30,000. Herbst Group LLC bought a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $28,000. Summit Financial LLC grew its holdings in shares of Esperion Therapeutics by 66.8% during the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 10,355 shares during the last quarter. Finally, PSI Advisors LLC grew its holdings in shares of Esperion Therapeutics by 161.5% during the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 10,500 shares during the last quarter. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.